SCHEMBL4786174

SCHEMBL4786174

OCc1cccc(-c2ccnc(Nc3cccc(O)c3)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK1 P53350 5/20 0.57
▸ SYK P43405 4/20 0.56
▸ CDK4 P11802 4/20 0.54
▸ CDK2 P24941 4/20 0.54
▸ CAMK2D Q13557 2/20 0.51
▸ KDR P35968 1/20 0.51
▸ PTK2 Q05397 1/20 0.51
▸ AURKB Q96GD4 1/20 0.51
▸ ABL1 P00519 4/20 0.49
▸ BCR P11274 4/20 0.49
▸ PRKCA P17252 2/20 0.49
▸ MAPK8 P45983 1/20 0.49
▸ PIK3CG P48736 1/20 0.49
▸ GSK3B P49841 1/20 0.49
▸ CAMKK2 Q96RR4 1/20 0.49
▸ PRKCD Q05655 1/20 0.49
▸ EGFR P00533 1/20 0.49
▸ SRC P12931 1/20 0.49
▸ PRKACA P17612 1/20 0.49
▸ PRKACG P22612 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4735323 0.95 PLK1 (0.57) PLK1SYKCDK4CDK2CAMK2D
SCHEMBL4737537 0.88 SYK (0.67) PLK1SYKCDK4CDK2CAMK2D
SCHEMBL12948401 0.87 SYK (0.58) PLK1SYKCDK4CDK2CAMK2D
SCHEMBL4732943 0.87 CDC7 (0.53) PLK1SYKCDK4CDK2CAMK2D
SCHEMBL4733635 0.86 PLK1 (0.56) PLK1SYKCDK4CDK2CAMK2D
SCHEMBL4737327 0.86 PLK1 (0.53) PLK1SYKCDK4CDK2CAMK2D
SCHEMBL12948400 0.86 PIK3CG (0.61) PLK1SYKCAMK2DKDRABL1
SCHEMBL4905928 0.82 PLK1 (0.72) PLK1SYKCDK4CDK2CAMK2D
SCHEMBL2945644 0.82 PLK1 (0.79) PLK1SYKCDK4CDK2CAMK2D
SCHEMBL4734812 0.82 ABL1 (0.71) PLK1CDK4CDK2AURKBABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 — — US claimed
WO-2008065155-A1 CDK INHIBITORS FOR TREATING PAIN INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-05 — — WO claimed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 — — US claimed
JP-2007500179-A — — 2007-01-11 — — JP claimed
CN-1860104-A 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LTD (GB) 2006-11-08 — — CN claimed
EP-1648875-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 — — EP claimed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 — — WO claimed
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 — — US disclosed
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 — — US disclosed
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 — — US disclosed
WO-2008065155-A1 CDK INHIBITORS FOR TREATING PAIN INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-05 — — WO disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 — — US disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 — — US disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 — — US disclosed
CN-1860104-A 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LTD (GB) 2006-11-08 — — CN disclosed
EP-1648875-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 — — EP disclosed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 — — WO disclosed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors GRK3, NCOR1, GRM3 PLK1 1603/4885SYK 1865/4885CDK4 642/4885
US-20080153822-A1 Methods of treating pain OPRL1, ACHE, OPRK1 PLK1 3544/4885SYK 1957/4885CDK4 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback